Business Context and Reporting Period
Company: Vanda Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 11, 2016
Context: The filing reports preliminary fourth quarter and full year 2015 results and provides 2016 financial guidance. The company is scheduled to present at the 34th Annual JP Morgan Healthcare Conference in San Francisco.
Key Financial Metrics
The filing text references a press release (Exhibit 99.1) containing specific numerical data for revenue, profit, cash flow, margins, debt, and liquidity. However, the provided text does not contain the actual numerical values for these metrics. It only confirms that preliminary results for Q4 2015 and full year 2015 were issued.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It states that the sections titled "Preliminary Fourth Quarter 2015 Results" and "Preliminary Full Year 2015 Results" are furnished as an exhibit and incorporated by reference, but the specific comparative data is not present in the main body of this document.
Guidance, Outlook, and Risks
- Guidance: The company issued 2016 financial guidance, detailed in the "2016 Financial Guidance" section of the attached press release (Exhibit 99.1).
- Outlook: Management is scheduled to meet with investors and analysts at the JP Morgan Healthcare Conference during the week of January 11, 2016.
- Legal Status: The financial results and guidance included in this filing are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2015 revenue, net loss, and cash position figures.
- Examine the 2016 Financial Guidance section in the press release for projected revenue and expense ranges.
- Access Exhibit 99.2 (Presentation Slides) for detailed management commentary and strategic outlook presented at the JP Morgan Healthcare Conference.
- Verify the company's cash runway and burn rate, as specific liquidity numbers are not listed in the 8-K text itself.